Kenvue Inc. $KVUE Shares Sold by First National Trust Co

First National Trust Co lessened its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 2.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 57,576 shares of the company’s stock after selling 1,409 shares during the quarter. First National Trust Co’s holdings in Kenvue were worth $1,205,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of KVUE. GAMMA Investing LLC increased its position in Kenvue by 33.2% during the 1st quarter. GAMMA Investing LLC now owns 24,778 shares of the company’s stock worth $594,000 after purchasing an additional 6,169 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its position in Kenvue by 4.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 106,140 shares of the company’s stock valued at $2,545,000 after acquiring an additional 4,034 shares in the last quarter. Golden State Wealth Management LLC grew its position in Kenvue by 292.0% in the first quarter. Golden State Wealth Management LLC now owns 3,081 shares of the company’s stock valued at $74,000 after acquiring an additional 2,295 shares in the last quarter. Robeco Institutional Asset Management B.V. grew its position in Kenvue by 2.6% in the first quarter. Robeco Institutional Asset Management B.V. now owns 103,091 shares of the company’s stock valued at $2,472,000 after acquiring an additional 2,576 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its position in Kenvue by 1.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 87,136 shares of the company’s stock valued at $2,081,000 after acquiring an additional 1,477 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Canaccord Genuity Group lowered their price objective on shares of Kenvue from $29.00 to $26.00 and set a “buy” rating for the company in a research report on Friday, August 8th. The Goldman Sachs Group lowered their price objective on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating for the company in a research report on Thursday, October 2nd. UBS Group lowered their price objective on shares of Kenvue from $23.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Rothschild & Co Redburn raised shares of Kenvue from a “neutral” rating to a “buy” rating and lowered their price objective for the company from $22.50 to $22.00 in a research report on Friday, September 26th. Finally, Royal Bank Of Canada lowered their price objective on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Kenvue has a consensus rating of “Hold” and an average price target of $20.90.

Kenvue Stock Down 3.9%

KVUE stock opened at $14.49 on Wednesday. Kenvue Inc. has a twelve month low of $14.05 and a twelve month high of $25.17. The company has a current ratio of 0.98, a quick ratio of 0.68 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $27.80 billion, a P/E ratio of 19.57, a PEG ratio of 2.18 and a beta of 0.72. The firm has a 50 day simple moving average of $17.64 and a 200-day simple moving average of $20.69.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. During the same quarter last year, the company earned $0.32 earnings per share. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. On average, equities research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.